Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Marie-Julie Nokin et al. published in the Journal of Thoracic Oncology:
“BRAF seen in 3-8% of NSCLC and while dabrafenib/trametinib and encorafenib/binimetinib approved for V600E, V600 accounts for only 35%.
This review in JTO and JTO CRR discusses biology and management BRAF non-V600, fusions, and other alterations.”
Title: Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.
Authors: Sandra Ortiz-Cuaran, Laurine Dupriez, Constance Nicq, Colin R. Lindsay, Julien Mazieres, David Santamaría, Chiara Ambrogio, Olivier Calvayrac, Cristina Teixido, Luc Friboulet, Silvia Novello, Fabrizio Tabbò, Aurélie Swalduz, Ernest Nadal, David Planchard, Laura Mezquita, and Marie-Julie Nokin.
You can read the full article in Journal of Thoracic Oncology.
More posts featuring Stephen Liu.